The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biodyn Regulatory News (OBD)

Share Price Information for Oxford Biodyn (OBD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.80
Bid: 7.80
Ask: 7.98
Change: -0.05 (-0.64%)
Spread: 0.18 (2.308%)
Open: 8.00
High: 8.10
Low: 7.80
Prev. Close: 7.85
OBD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

3 Oct 2023 16:37

RNS Number : 5742O
Oxford BioDynamics PLC
03 October 2023
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BD5H8572

Issuer Name

Oxford BioDynamics Plc

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

SENECA PARTNERS LIMITED

City of registered office (if applicable)

 

Country of registered office (if applicable)

UK

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

PLATFORM SECURITIES NOMINEES LIMITED

WOODSIDE NOMINEES LIMITED

City of registered office (if applicable)

LONDON

Country of registered office (if applicable)

UK

5. Date on which the threshold was crossed or reached

02-OCT-2023

6. Date on which Issuer notified

03-OCT-2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

4.930000

0.000000

4.930000

9,978,822

Position of previous notification (if applicable)

5.720000

0.000000

5.720000

11,578,822

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BD5H8572   

9,978,822

4.930000

Sub Total 8.A

9,978,822

4.930000

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

03-OCT-2023

13. Place Of Completion

Haydock UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEASEDEDKDFFA
Date   Source Headline
18th Sep 20187:00 amRNSConsortium with OBD receives ?4m Horizon 2020 fund
4th Sep 201810:03 amRNSTotal Voting Rights
30th Aug 20182:57 pmRNSHolding(s) in Company
29th Aug 20184:52 pmRNSHolding(s) in Company
29th Aug 20184:48 pmRNSHolding(s) in Company
29th Aug 20184:47 pmRNSHolding(s) in Company
29th Aug 20184:46 pmRNSHolding(s) in Company
29th Aug 20184:43 pmRNSHolding(s) in Company
22nd Aug 20187:00 amRNSChinese Investment Group Takes Stake in OBD
19th Jul 20187:00 amRNSGrant of Canadian patent for EpiSwitch platform
17th Jul 20187:00 amRNSOBD presents latest EpiSwitch data at ASH Summit
2nd Jul 20185:50 pmRNSTotal Voting Rights
26th Jun 20187:00 amRNSALS study published in peer reviewed journal
19th Jun 20187:00 amRNSIssue of Equity
22nd May 20187:00 amRNSInterim Results for the Period Ended 31 March 2018
1st May 20187:00 amRNSTotal Voting Rights
17th Apr 20187:00 amRNSNotice of Interim Results
5th Apr 201811:41 amRNSIssue of Equity
28th Mar 20187:00 amRNSPublication in Journal of Translational Medicine
19th Mar 20187:00 amRNSPDMR Dealing/Grant of Share Options
16th Mar 20187:00 amRNSALS biomarker data presented at World CNS Summit
15th Mar 20182:10 pmRNSResults of Annual General Meeting
15th Feb 20187:00 amRNSPublication of Annual Report and Notice of AGM
14th Feb 20181:11 pmRNSGrant of Indian patent for EpiSwitch platform
30th Jan 20187:01 amRNSShore Capital appointed as NOMAD and Sole Broker
30th Jan 20187:00 amRNSFinal Results for the Year Ended 30 September 2017
29th Jan 20187:00 amRNSCollaboration in sports-related concussions
16th Jan 20187:00 amRNSNotice of Results
5th Jan 20183:05 pmRNSHolding(s) in Company
3rd Jan 20187:00 amRNSSigns 2nd agreement with US biopharma company
2nd Jan 20183:00 pmRNSTotal Voting Rights
21st Dec 20177:00 amRNSDirector/PDMR Shareholding
13th Dec 20177:01 amRNSExercise period extension existing Share Options
5th Dec 20177:00 amRNSEXERCISE OF WARRANTS AND DIRECTOR DEALING
15th Nov 20177:00 amRNSData at FNIH Biomarker Consortium Cancer Meeting
7th Nov 20177:00 amRNSAgreement with a major US biopharma company
6th Nov 201712:29 pmRNSNotification of major holdings
13th Oct 20177:00 amRNSPresents at the Diabetes Asia 2017 Conference
11th Oct 20177:00 amRNSPresents ALS signatures at NEALS
3rd Oct 20177:00 amRNSAnnounces grant of US patent for EpiSwitchT
28th Sep 20177:00 amRNSSuccessful in diagnosing and staging breast cancer
15th Sep 20177:00 amRNSDirectorate Update
30th Jun 20177:00 amRNSAppointment of Paul Stockdale as CFO
13th Jun 20177:00 amRNSInterim Results
13th Jun 20177:00 amRNSTargets Amyotrophic Lateral Sclerosis in Asia
31st May 20177:00 amRNSPublication highlights advantages of EpiSwitchT
31st May 20177:00 amRNSNotice of Interim Results
23rd May 20177:00 amRNSDevelopment Agreements with Top Pharma Companies
19th May 20177:00 amRNSAppointment of Shore Capital as Joint Broker
18th May 20177:00 amRNSSubsidiary signs exclusive Asia licence

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.